Early Bird Special (EBS)

[Bunny]

LIV amaritan's Adult Stem Cell Drug Displays Money-Making Signs
Business Wire - March 21, 2006 10:29

LAS VEGAS, Mar 21, 2006 (BUSINESS WIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today its Alzheimer's adult stem cell drug SP-sc04, which induces dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells, is progressing through preclinical studies with promising results.

According to a CEO Magazine March 2006 article titled "Have Stem Cells Arrived?" Fran Hawthorne stated, "signs point to an emerging, money-making industry" and William R. Brody, president of Johns Hopkins University, is quoted, "I don't think I have ever seen anything that has the broad potential that stem cell technology has."

"We are extremely pleased with the progress and the potential of SP-04. Although it is early stage, each preclinical study we accomplish gives us hope that we might have an extraordinary treatment for the mind robbing disease of Alzheimer's," stated Dr. Greeson, CEO of Samaritan.

http://www.chiefexecutive.net/ME2/dirmod.asp?sid=&nm=&type=Publish ing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791 &tier=4&id=A83BC9A72A074876BCA05E0ED18D56E2

Samaritan Pharmaceuticals: "We LIV....to Save Lives."

Samaritan is a small-cap biotech, driven to discover, develop and commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease. Look at www.samaritanpharma.com. Please register on Web site so we can notify you of upcoming conference calls, news and events.

Disclaimer

he company disclaims any information that is created by an outside party, and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

SOURCE: Samaritan Pharmaceuticals Inc.

Samaritan Pharmaceuticals Inc., Las Vegas
Gene Boyle, 702-735-7001
[e-mail]

Copyright Business Wire 2006





--------------------------------------------------------------------------------



Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.



News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.

Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.